Document is current
Any future updates will be listed below
-
Authors
Pulanic, Drazen https://orcid.org/0009-0004-3755-4477
Peczynski, Christophe
Boreland, William https://orcid.org/0009-0007-9739-0816
Rautenberg, Christina https://orcid.org/0000-0002-0611-1372
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Michonneau, David https://orcid.org/0000-0003-4553-3065
Salmenniemi, Urpu
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Egger-Heidrich, Katharina
Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Blaise, Didier https://orcid.org/0000-0002-5684-9447
Luft, Thomas https://orcid.org/0000-0002-0387-1640
Labussière-Wallet, Hélène
Moiseev, Ivan https://orcid.org/0000-0002-4332-0114
Koenecke, Christian https://orcid.org/0000-0001-7025-1735
Schoemans, Helene https://orcid.org/0000-0002-7568-8239
Basak, Grzegorz
Penack, Olaf https://orcid.org/0000-0003-4876-802X
Peric, Zinaida
- License Information
-
More Information
Article History
Received: 11 April 2025
Revised: 13 July 2025
Accepted: 5 August 2025
First Online: 19 August 2025
Competing interests
: DP received honoraria from Novartis and Takeda. NK received honoraria from Sanofi and Neovii. DM received research grants from Novartis, Sanofi and CSL Behring, consulting fees from Novartis, Incyte, Sanofi, Jazz Pharmaceuticals, and Mallinckrodt. RZ received honoraria from Novartis, Incyte, Sanofi, Medac and Mallinckrodt. KEH received travel support and honoraria from Beigene, Sanofi, Johnson&Johnson and Servier. IM received honoraria from Novartis, Sanofi, J&J. OP has received honoraria or travel support from Alexion, Gilead, Jazz, MSD, Neovii, Novartis, Pfizer and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Apogepha, Alexion, Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Orca Bio, Priothera, Sanofi, Shionogi and SOBI. OP acknowledges the support of José Carreras Leukämie-Stiftung (3 R/2019, 23 R/2021), Deutsche Krebshilfe (70113519), Deutsche Forschungsgemeinschaft (PE 1450/7-1, PE 1450/9-1, PE 1450/10-1, PE 1450/11-1) and Stiftung Charité BIH (BIH_PRO_549, Focus Group Vascular Biomedicine). ZP received honoraria from Therakos, Sanofi and Novartis.
: The study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by the scientific board of the Transplant Complications Working Party of EBMT. As per EBMT data collection policies, written informed consent was obtained from all patients for the use of their data. All methods were conducted in accordance with relevant guidelines and regulations.
